Pith. sign in

Pith Integrity · Reference Change Desk · events-only

Reference changes

See every place this corpus cites a work that was later retracted, corrected, withdrawn, or placed under expression of concern: exact quote, event source, and what happened next. No model judges the citation.

A notice on this page means a citing paper's bibliography includes a work with a published scholarly-record event. It is not a judgment on the citing paper.

Scoped to citing paper 2501.08744 · clear

01Events with corpus notices

02One-hop citation notices (secondary index)

Correction Crossref Open
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab

cites 10.1016/s1470-2045(11)70037-7 · ref [10] · event 2011-08-02 · 2501.08744 · event page · DOI 10.1016/s1470-2045(11)70037-7

Raw extraction · citation context

DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or 26 metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12: 369-376. 20110321. DOI: 10.1016/s1470-2045(11)70037-7. 52. Martín M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to…

Parser render (TeX stripped for reading; raw above is the evidence)

DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or 26 metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12: 369-376. 20110321. DOI: 10.1016/s1470-2045(11)70037-7. 52. Martín M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to…

Correction Crossref Open
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab

cites DOI: 10.1016/s1470-2045(14)70381-x · ref [1244] · event 2014-09-30 · 2501.08744 · event page · DOI 10.1016/s1470-2045(14)70381-x

Raw extraction · citation context

Ann Oncol 2010; 21: 1804-1809. 20100211. DOI: 10.1093/annonc/mdq020. 78. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15: 1236-1244. 20140827. DOI: 10.1016/s1470-2045(14)70381-x. 79. Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab vs erlotin…

Parser render (TeX stripped for reading; raw above is the evidence)

Ann Oncol 2010; 21: 1804-1809. 20100211. DOI: 10.1093/annonc/mdq020. 78. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15: 1236-1244. 20140827. DOI: 10.1016/s1470-2045(14)70381-x. 79. Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab vs erlotin…

Correction Crossref Open
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab

cites Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial · ref [9] · event 2011-08-03 · 2501.08744 · event page · DOI 10.1016/j.clbc.2011.03.005

Raw extraction · citation context

for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719- 1725. 20130408. DOI: 10.1200/jco.2012.44.7912. 50. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82-92. 20110411. DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or…

Parser render (TeX stripped for reading; raw above is the evidence)

for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719- 1725. 20130408. DOI: 10.1200/jco.2012.44.7912. 50. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82-92. 20110411. DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or…

Correction Crossref Open
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab

cites 10.1200/jco.2015.61.5005 · ref [32] · event 2016-08-24 · 2501.08744 · event page · DOI 10.1200/jco.2015.61.5005

Raw extraction · bibliography line

Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: Retrospective analysis of the A V Aglio trial. J Clin Oncol 2015; 33: 2735-2744. 20150629. DOI: 10.1200/jco.2015.61.5005